<DOC>
	<DOCNO>NCT00354939</DOCNO>
	<brief_summary>Primary objective : Difference frequency subject conventionally detect hypoglycemia subject [ least one measurement smaller/equal 60mg/dl document 8-point profile case record form ( CRF ) documentation symptomatic hypoglycemia CRF Visits 8/9 ] compare CGMS detect blood glucose value smaller/equal 60mg/dl CGMS measurement ( least one measurement Visits 8/9 ) eight week treatment insulin glargine . Secondary objective : Secondary study objective investigate safety efficacy treatment change insulin glargine ICT treat subject term : - Percentage blood glucose measurement ( CGMS data ) smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Percentage nocturnal blood glucose measurement ( CGMS data ) smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Percentage daytime blood glucose measurement ( CGMS data ) smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Area curve ( AUC smaller/equal 60 ) time ( smaller/equal 60 ) blood glucose smaller/equal 60mg/dl [ 3.3mmol/l ] , area curve ( AUC greater/equal 180 ) time ( greater/equal 180 ) blood glucose greater/equal 180mg/dl [ 10.0mmol/l ] . - Area curve ( AUC smaller/equal 60 ) time ( smaller/equal 60 ) blood glucose smaller/equal 60mg/dl [ 3.3mmol/l ] day ( AUC 06.00am - 10.00pm ) night ( AUC 10.00pm - 06.00am ) . - Area curve ( AUC greater/equal 180 ) time ( greater/equal 180 ) blood glucose greater/equal 180mg/dl [ 10.0mmol/l ] day ( AUC 06.00am - 10.00pm ) night ( AUC 10.00pm - 06.00am ) . - Frequency subject nocturnal blood glucose value smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject asymptomatic nocturnal blood glucose smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject symptomatic nocturnal blood glucose smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject daytime blood glucose smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject asymptomatic daytime blood glucose smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject symptomatic daytime blood glucose smaller/equal 60mg/dl [ 3.3 mmol/l ] . - Frequency subject hyperglycemic blood glucose ( greater/equal 180mg/dl , [ 10.0mmol/l ] ) . - Frequency subject symptomatic hypoglycemia ( smaller/equal 60mg/dl [ 3.3mmol ] ) . - Frequency subject severe hypoglycemia ( smaller/equal 36mg/dl [ 2.0mmol/l ] ) . - Blood glucose value 8-point profile . - Mean daytime &amp; mean nocturnal blood glucose 8-point-profiles . - HbA1c . - Fasting blood glucose ( FBG ) . - Dose insulin . - Adjustment insulin . - Body weight , body mass index .</brief_summary>
	<brief_title>Insulin Analogue With Continuous Glucose Monitoring System ( CGMS ) Measurement</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus ( history ketoacidosis ) stable treatment NPH insulin ( twice daily ) mealtime insulin least 3 month . HbA1c value smaller/equal 8.0 % ( measure screen visit , Visit 1 ) . Ability willingness perform continuous self monitoring blood glucose profile , use self monitor blood glucose meter well carry continuous blood glucose meter least two time 72 hour throughout study home . All form diabetes type 2 diabetes mellitus . Oral antidiabetic drug ( OADs ) and/or insulin NPH mealtime insulin , except metformin ( stable dose minimum 3 month , dose adjustment study ) . Pregnant ( determine urine pregnancy test Visit 1 ) breastfeeding . Women childbearing potential take adequate contraceptive protection systemic hormone plan become pregnant study . Likelihood require treatment study period drug permit study protocol ( e.g . systemic corticosteroid ) . History hypersensitivity study medication drug similar chemical structure . Treatment investigational drug last month study entry . History drug alcohol abuse . Diabetic retinopathy surgical treatment ( laser photocoagulation vitrectomy ) 3 month prior study entry require surgical treatment within study . Clinically relevant cardiovascular , gastrointestinal , hepatic , neurological , endocrine , hematological major systemic disease make implementation protocol interpretation study result difficult . Known impaired hepatic renal function . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>